Advanced Therapies Week 2022 | Supporting apheresis and manufacturing processes in the CGT space

Delara Motlagh, PhD, MS, EMBA, Terumo Blood and Cell Technologies, Lakewood, CO, comments on the current activity of Terumo Blood and Cell Technologies within the cell and gene therapy (CGT) sector. The Spectra Optia system enables apheresis and cell collection from patients, an important process where a vast majority of advanced therapies begin with apheresis. Dr Motlagh additionally describes the Quantum Cell Expansion System, which provides a platform to scale-up cell expansion and modification in a sterile environment. This interview took place at Advanced Therapies Week 2022.